Celaid Therapeutics Inc. Celaid has teamed up with AGC Inc. for a collaborative research agreement. AGC focuses on advancing hematopoietic stem and progenitor cells from induced pluripotent stem cells (iPSC-HSPCs). The partnership aims to combine Celaid’s unique hematopoietic stem cell (HSC) expansion platform with AGC’s iPSC technology. This will allow for better and larger-scale growth of iPSC-HSPCs. Celaid’s HSC expansion technology will be used with AGC’s iPSC-HSPCs. The expanded cells will then be tested for functionality in the lab and in animal studies. The initiative seeks to create a way for large-scale production of high-quality iPSC-HSPCs. It aims to tackle important manufacturing challenges in developing iPSC-based blood and immune cell therapies. Also Read: Asahi Kasei Opens New Plant to Boost Planova Output "We're excited to team up with AGC. Together,…
Sign in to your account